

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-12. (Cancelled)

13. (Previously Presented) A method of inhibiting lymphocyte activation, comprising administering to a patient in need thereof an antibody that binds to a protein having an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 1.

14. (Withdrawn) A method according to claim 13, wherein the lymphocytes are T cells.

15. (Previously Presented) A method according to claim 13, wherein the lymphocytes are B cells.

16. (Previously Presented) A method according to claim 13, wherein the antibody is a monoclonal antibody.

17. (Previously Presented) A method according to claim 16, wherein the antibody comprises a constant region of human antibody.

18. (Previously Presented) A method according to claim 16, wherein the antibody is a chimeric antibody or humanized antibody.

19. (Previously Presented) A method according to claim 16, wherein the antibody is an anti-HM1.24 antibody.

20. (Previously Presented) A method according to claim 18, wherein the antibody is a chimeric anti-HM1.24 antibody.

21. (Previously Presented) A method according to claim 18, wherein the antibody is a humanized anti-HM1.24 antibody.

22. (Previously Presented) A method according to claim 1, wherein the antibody binds to an epitope recognized by an anti-HM1.24 antibody.

23. (Previously Presented) A method of treating a disease associated with lymphocyte activation, comprising administering to a patient in need thereof an antibody that binds to a protein having an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 1.

24. (Previously Presented) A method according to claim 23, wherein said disease is selected from the group consisting of autoimmune disease, rejection in organ transplantation, and allergy.